Perjeta regimen may help people with HER2-positive early breast cancer live longer wi

[News]

New data show that adding the personalised therapy, Perjeta to Herceptin® (trastuzumab) and docetaxel chemotherapy in the neoadjuvant setting (before surgery), may cut the risk of disease...

More... (http://www.medicalnewstoday.com/releases/294727.php)